AIM ImmunoTech (NYSE:AIM) Stock Price Up 6.5%

AIM ImmunoTech Inc. (NYSE:AIM) was up 6.5% during mid-day trading on Tuesday . The company traded as high as $0.46 and last traded at $0.49, approximately 89,930 shares changed hands during mid-day trading. A decline of 63% from the average daily volume of 244,692 shares. The stock had previously closed at $0.46.

Separately, Maxim Group raised shares of AIM ImmunoTech from a “hold” rating to a “buy” rating in a report on Thursday, October 10th.

The company has a debt-to-equity ratio of 0.33, a current ratio of 3.01 and a quick ratio of 3.01. The business’s 50 day moving average is $0.50.

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC bought a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 185,171 shares of the company’s stock, valued at approximately $141,000. Sabby Management LLC owned 2.24% of AIM ImmunoTech as of its most recent SEC filing. 41.19% of the stock is currently owned by hedge funds and other institutional investors.

AIM ImmunoTech Company Profile (NYSE:AIM)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).

Featured Article: What impact do institutional investors have on markets?

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with's FREE daily email newsletter.